Takeda Invests ¥150 Million For Nanoparticle Vaccine Research
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has started a joint research program with Osaka University (Handai) to commercialize vaccines containing nanoparticles.